[1] Chen A X, Burt M G.Hyperprolactinaemia[J]. Aust Prescr, 2017, 40(6): 220-224. [2] Ricardo V L, Robert Y O, Gunter K, Juan R.WHO classification of tumours of endocrine organ[M]. Lyon, International agency for research on cancer (IARC).2017: 24-27. [3] Inoshita N, Nishioka H. The2017 WHO classification of pituitary adenoma: overview and comments[J]. Brain Tumor Pathol, 201835(2):51-56. [4] 时景仁, 郭向华, 王珊珊, 等. 成像流式细胞仪检测细胞自噬水平研究[J]. 国际检验医学杂志, 2016, 37(21):2949-2951. [5] Saleem M, Martin H, Coates P.Prolactin Biology and Laboratory Measurement: An Update on Physiology and Current Analytical Issues[J]. Clin Biochem Rev, 2018, 39(1):3-16. [6] Gao H, Wang F, Lan X, et al.Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.[J]. Bmc Cancer, 2015, 15(1):272. [7] 田野, 李周, 高昊,等. 国内已上市辅助肿瘤治疗中成药研究进展[J]. 药学研究, 2018, 37(1):35-40. [8] 郑淑荣,高华,李丹,等. 高内涵技术筛选抑制GH3细胞的天然黄酮类化合物的研究[J]. 中国药物警戒, 2018, 15(5): 257-259. [9] 王红云, 龚磊, 刘春晖,等. 雌激素受体1在生长激素腺瘤中的表达及意义[J]. 中华神经外科杂志, 2017, 33(6): 610-614. [10] Zhang W, Pan Y, Gou P, et al.Effect of xanthohumol on Th1/Th2 balance in a breast cancer mouse model[J]. Oncology Reports, 2018, 39(1):280-288. [11] 时景仁, 郭向华, 王珊珊,等. 成像流式细胞仪检测细胞自噬水平研究[J]. 国际检验医学杂志, 2016, 37(21):2949-2951. |